Dexcom G7 Receives FDA Approval!
Today is the day and the Juicebox Podcast has all the info you want about the Dexcom G7.
Episode 676 - Jake Leach Executive Vice President and Chief Technology Officer at Dexcom is back to talk G7.
https://www.juiceboxpodcast.com/episodes/jbp676
Episode 782 - Emily's son has type 1 diabetes and he uses the Dexcom G7.
https://www.juiceboxpodcast.com/episodes/jbp782
Episode 768 - Dexcom Senior Director of Global Product Design, Alex Diener has type 1 diabetes and he's here to talk about designing the Dexcom G7.
https://www.juiceboxpodcast.com/episodes/jbp768
LEARN MORE ABOUT Dexcom http://bit.ly/DexAd
listen free
Apple Podcasts ⇢ http://bit.ly/JBPAPod
Spotify ⇢ http://bit.ly/JBPspot
Amazon Music ⇢ https://bit.ly/JBPAmazonMusic
Audible ⇢ https://adbl.co/3KA4J5S
Android ⇢ http://bit.ly/jbpandroid
Pandora ⇢ http://bit.ly/pandorajbp
Google Podcast ⇢ http://bit.ly/JBPgoogle
online ⇢ http://bit.ly/JuiceboxPod
Insulin Supply Disruption
After a number of people in the Juicebox Podcast private Facebook group reported having trouble getting some of their Novo Nordisk brand insulins, I reached out to Novo Nordisk to see if I could learn more. Their responses is below.
Novo Nordisk is currently experiencing some supply disruptions causing pockets of stock outages for several of our products across the US, including our insulins. At this time, shortages are being seen across our portfolio of insulin products. The disruption was caused by a temporary manufacturing issue that has now been resolved as well as general COVID-related shipping delays and materials sourcing. Importantly, supply is now consistently shipping out across the US from our warehouses, and we expect stock in pharmacies to be normalized in December. There are no supply issues impacting the Novo Nordisk GLP-1 diabetes products (Victoza, Ozempic, Rybelsus).
We encourage anyone who needs medicine now and can’t get it to speak to their health care provider about an appropriate treatment plan. We know this is a source of frustration and concern for those who rely on our medicines. We take our responsibility very seriously to supply the market with our medicine and we’re working hard to rectify the situation.
Dexcom G6 Meets Garmin
Press Release
LATHE, Kan./October 13, 2021/Business Wire – Garmin® International, Inc., a unit of Garmin Ltd. (NASDAQ: GRMN), today introduced the Dexcom Connect IQ apps, providing people with Type 1 and Type 2 diabetes who use the Dexcom® G6 Continuous Glucose Monitor (CGM) System1 with a way to quickly see their glucose levels and trends – even while working out – right on their compatible Garmin smartwatch or cycling computer.2 The apps can be downloaded now from the Connect IQ™ store.
“Dexcom’s CGM systems have revolutionized how people live with diabetes, and we are thrilled to offer our customers an even more convenient way to see their glucose levels,” said Dan Bartel,Garmin vice president of worldwide sales. “Users can not only see which way their glucose levels are trending without having to take their phone out, but can even do so while working out, when glucose levels have the potential to fluctuate quickly.”
The Dexcom Connect IQ apps, developed by Garmin, make it easy for people with diabetes to keep an eye on their glucose numbers at any time.
During the Day
Available for a wide range of Garmin smartwatches, the Dexcom Connect IQ app3 provides people with diabetes with a secondary way to view their glucose levels, right from their wrist. With their smartphone stowed away4, the app allows people with diabetes to see glucose levels and trends to get a clearer picture of where their numbers are heading, as well as a 3-hour history of glucose levels to look back on.
During an Activity
While out for a run, bike ride or other adventure, the Dexcom Connect IQ data field3 provides people with diabetes with a secondary way to view both their glucose levels and performance stats all in one place, so they can focus more on their workout. When training or racing with a compatible smartwatch or Edge® cycling computer, users can keep an eye on their glucose levels and trends, as well as their performance data, right on their Garmin device without pulling out their smartphone.4,5
“The addition of Garmin wearables and cycling computers to the Dexcom CGM ecosystem is an exciting advancement for Dexcom users who are now able to easily view and monitor their glucose levels from their favorite Garmin device,” said Jake Leach, chief technology officer at Dexcom. “Garmin is our first partner to connect to Dexcom G6 through our new real-time API – showcasing the value of integrated CGM and further solidifying Dexcom G6 as the most powerful and connected CGM in the world.”
The Dexcom Connect IQ apps are available for download from the Connect IQ Store now for customers in the United States.
Dexcom G6 App Update
Dexcom BGs right on your iPhone home screen with widgets
Dexcom G6 Covered 100% for Veterans
Dexcom G6 Continuous Glucose Monitoring System Now Available at Veterans Affairs Pharmacies Across the United States
New government contract and pharmacy availability improves access to Dexcom G6 continuous glucose monitoring for hundreds of thousands of veterans with diabetes
Prescribing Dexcom G6 is now more cost effective and efficient for the VA than the previous procurement pathway
The cost of Dexcom CGM is 100% covered by the VA for patients with Type 1 or Type 2 diabetes who meet eligibility criteria
To be eligible for Dexcom G6 coverage under Veterans Affairs, a healthcare provider must verify that the patient meets the following qualifying criteria:
Has diabetes
Performs frequent blood glucose monitoring (BGM) testing (≥4x/day)
Takes ≥3 daily injections of insulin or uses an insulin pump
Has the skillset and knowledge to use CGM successfully
Has agreed to follow up in the clinic a minimum of every 6 months
And, is one or more of the following:
At risk for hypoglycemia
Unable to meet glycemic control, despite adherence to the treatment regimen
Performs job-related activities where a hypoglycemic event could put them at risk of harm
Unable to perform self-monitoring of blood glucose due to disability or disease